- a) Pegaptanib sodium (Macugen)
- b) Verteporfin (Visudyne PDT)
- c) Ranibizumab (Lucentis)
- d) Bevacizumab (Avastin)
- e) All of the above
Correct Answer: Bevacizumab (Avastin)
Bevacizumab given intravitreally is a common off-label treatment for all CNV lesion subtypes in any fundus location in neovascular AMD, but is not specifically FDA approved for this indication.